运用计算机模拟和体外实验方法鉴定和重新利用抗严重急性呼吸综合征冠状病毒2的抗病毒药物。
Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
作者信息
Watashi Koichi
机构信息
Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Applied Biological Sciences, Tokyo University of Science, Noda, 278-8510, Japan; Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, 606-8507, Japan; MIRAI, JST, Saitama, 332-0012, Japan.
出版信息
Biochem Biophys Res Commun. 2021 Jan 29;538:137-144. doi: 10.1016/j.bbrc.2020.10.094. Epub 2020 Nov 20.
Abstract
Coronavirus infectious diseases 2019 (COVID-19), a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a serious public health threat worldwide. So far, there are no drugs and vaccines whose efficacy has been well-proven. After the outbreak, there has been a massive search for anti-SARS-CoV-2 medications, focusing on approved drugs because repurposing approved drugs will take less time to reach clinical usage than new drugs. This article summarizes the studies using in silico and in vitro approaches to identify therapeutic candidates among approved drugs that target the SARS-CoV-2 life cycle.
摘要
2019年冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的全球大流行疾病，已成为全球严重的公共卫生威胁。到目前为止，尚无疗效得到充分证实的药物和疫苗。疫情爆发后，人们对抗SARS-CoV-2药物进行了大规模搜索，重点是已获批药物，因为将已获批药物重新用于治疗所需的时间比新药更短，能更快进入临床应用。本文总结了利用计算机模拟和体外方法在已获批药物中寻找针对SARS-CoV-2生命周期的治疗候选药物的研究。
相似文献
1
Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
Biochem Biophys Res Commun. 2021 Jan 29;538:137-144. doi: 10.1016/j.bbrc.2020.10.094. Epub 2020 Nov 20.
2
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
Future Microbiol. 2021 Nov;16:1341-1370. doi: 10.2217/fmb-2021-0019. Epub 2021 Nov 10.
3
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2105815118.
4
High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
PLoS One. 2021 Apr 22;16(4):e0250019. doi: 10.1371/journal.pone.0250019. eCollection 2021.
5
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Cells. 2021 Dec 24;11(1):52. doi: 10.3390/cells11010052.
6
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Viruses. 2020 Dec 5;12(12):1394. doi: 10.3390/v12121394.
7
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
mBio. 2021 Mar 30;12(2):e03681-20. doi: 10.1128/mBio.03681-20.
8
Repurposing Nucleoside Analogs for Human Coronaviruses.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01652-20.
9
Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
Curr Pharm Biotechnol. 2021;22(2):192-199. doi: 10.2174/1389201021999200820155927.
10
Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19.
OMICS. 2020 Oct;24(10):568-580. doi: 10.1089/omi.2020.0071. Epub 2020 Jul 30.
引用本文的文献
1
Therapeutics for COVID-19.
Nat Microbiol. 2023 May;8(5):771-786. doi: 10.1038/s41564-023-01356-4. Epub 2023 May 4.
2
Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.
Can J Infect Dis Med Microbiol. 2022 Sep 25;2022:2044282. doi: 10.1155/2022/2044282. eCollection 2022.
3
Lack of efficacy of mono-mode of action therapeutics in COVID-19 therapy - How the lack of predictive power of preclinical cell and animal studies leads developments astray.
Chem Biol Drug Des. 2022 Jan;99(1):32-45. doi: 10.1111/cbdd.13954. Epub 2021 Oct 31.
4
Advances in the computational landscape for repurposed drugs against COVID-19.
Drug Discov Today. 2021 Dec;26(12):2800-2815. doi: 10.1016/j.drudis.2021.07.026. Epub 2021 Jul 30.
5
Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro.
Int J Mol Sci. 2021 Mar 19;22(6):3163. doi: 10.3390/ijms22063163.
6
SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.
Molecules. 2021 Mar 5;26(5):1409. doi: 10.3390/molecules26051409.
7
Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19.
Saudi J Biol Sci. 2021 May;28(5):3152-3159. doi: 10.1016/j.sjbs.2021.02.059. Epub 2021 Feb 23.
本文引用的文献
1
SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response.
Cell Stem Cell. 2020 Dec 3;27(6):962-973.e7. doi: 10.1016/j.stem.2020.09.013. Epub 2020 Sep 18.
2
A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
J Biomol Struct Dyn. 2022 Feb;40(3):1101-1108. doi: 10.1080/07391102.2020.1822209. Epub 2020 Sep 18.
3
Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.
Bioorg Chem. 2020 Nov;104:104269. doi: 10.1016/j.bioorg.2020.104269. Epub 2020 Sep 8.
4
Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
EMBO J. 2020 Nov 2;39(21):e106057. doi: 10.15252/embj.2020106057. Epub 2020 Oct 5.
5
High Potency of a Bivalent Human V Domain in SARS-CoV-2 Animal Models.
Cell. 2020 Oct 15;183(2):429-441.e16. doi: 10.1016/j.cell.2020.09.007. Epub 2020 Sep 4.
6
Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an structure-based approach.
J Biomol Struct Dyn. 2022 Feb;40(2):918-930. doi: 10.1080/07391102.2020.1819882. Epub 2020 Sep 16.
7
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
Cell. 2020 Oct 1;183(1):169-184.e13. doi: 10.1016/j.cell.2020.08.026. Epub 2020 Aug 19.
8
Infection of Brain Organoids and 2D Cortical Neurons with SARS-CoV-2 Pseudovirus.
Viruses. 2020 Sep 8;12(9):1004. doi: 10.3390/v12091004.
9
Crystal structure of SARS-CoV-2 papain-like protease.
Acta Pharm Sin B. 2021 Jan;11(1):237-245. doi: 10.1016/j.apsb.2020.08.014. Epub 2020 Sep 2.
10
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Nat Commun. 2020 Sep 4;11(1):4417. doi: 10.1038/s41467-020-18233-x.
Zotero 插件